A reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat

Trial Profile

A reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 According to an Amicus Therapeutics media release, 179 patients (treatment naive and ERT switch) reimbursed Galafold as of July 31, 2017.
    • 09 May 2017 According to an Amicus Therapeutics media release, 100 patients (treatment naive and ERT switch) reimbursed Galafold as of April 30, 2017
    • 09 Jan 2017 According to an Amicus Therapeutics media release, 61 patients are being treated on reimbursed Galafold as of December 31, 2016. The company targets to treat 300 patients by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top